Literature DB >> 1856924

Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.

R Klän1, V Loy, H Huland.   

Abstract

When a second transurethral resection was routinely performed 8 to 14 days after the initial transurethral resection in 46 patients for stage T1 bladder tumors residual disease was found in 20 despite the surgical report of complete resection in 40. In only 13 patients was residual tumor noted at repeat resection by the senior urologist performing the operation and residual tumor was confirmed histologically in 10 of them. The extent of the lesion is easily misjudged even by experienced surgeons. Early cystoscopy cannot exclude residual tumor. Residual tumor is an important cause of early recurrence and repeat resection of stage T1 lesions is recommended.

Entities:  

Mesh:

Year:  1991        PMID: 1856924     DOI: 10.1016/s0022-5347(17)37779-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  28 in total

Review 1.  Current problems and needs in the treatment of pT1 G3 bladder carcinoma.

Authors:  Francisco Jose Martínez Portillo; Peter Alken
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 2.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system.

Authors:  Adam Kinnaird; Peter Dromparis; Howard Evans
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

4.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

5.  Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.

Authors:  Hung-Lung Ke; Jie Lin; Yuanqing Ye; Wen-Jeng Wu; Hui-Hui Lin; Hua Wei; Maosheng Huang; David W Chang; Colin P Dinney; Xifeng Wu
Journal:  Ann Surg Oncol       Date:  2015-04-08       Impact factor: 5.344

6.  Application of new technology in bladder cancer diagnosis and treatment.

Authors:  Alvin C Goh; Seth P Lerner
Journal:  World J Urol       Date:  2009-02-22       Impact factor: 4.226

7.  Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer.

Authors:  Hung-Lung Ke; Meng Chen; Yuanqing Ye; Michelle A T Hildebrandt; Wen-Jeng Wu; Hua Wei; Maosheng Huang; David W Chang; Colin P Dinney; Xifeng Wu
Journal:  Carcinogenesis       Date:  2013-01-14       Impact factor: 4.944

8.  Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results?

Authors:  Wolfgang Otto; Maximilian Burger; Hans-Martin Fritsche; Andreas Blana; Wolfgang Roessler; Ruth Knuechel; Wolf F Wieland; Stefan Denzinger
Journal:  Clin Med Oncol       Date:  2009-04-30

9.  [Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study].

Authors:  T Filbeck; U Pichlmeier; R Knuechel; W F Wieland; W Rössler
Journal:  Urologe A       Date:  2003-04-25       Impact factor: 0.639

Review 10.  [Interdisciplinary strategies for the treatment of bladder cancer].

Authors:  Wilhelm Bauer; Michael Lamche; Paul Schramek
Journal:  Wien Med Wochenschr       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.